Assuntos: VACINAÇÃO, SÍNDROME CORONARIANA AGUDA, MORTALIDADE, INFLUENZA
ABNT
FONSECA, Henrique Andrade R et al. In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: a prespecified analysis of the VIP-ACS trial. Vaccine, v. 42, n. 3, p. 496-504, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/58827. Acesso em: 06 nov. 2024.APA
Fonseca, H. A. R., Zimerman, A., Monfardini, F., Guimaraes, H. P., Pedrosa, R. P., Patriota, R. de L. S., et al. (2024). In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: a prespecified analysis of the VIP-ACS trial. Vaccine, 42( 3), 496-504. doi:10.1016/j.vaccine.2023.12.074NLM
Fonseca HAR, Zimerman A, Monfardini F, Guimaraes HP, Pedrosa RP, Patriota R de LS, Patriota TLGC, Passos LCS, Dall'orto FTC, Nicolau JC. In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: a prespecified analysis of the VIP-ACS trial [Internet]. Vaccine. 2024 ; 42( 3): 496-504.[citado 2024 nov. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58827Vancouver
Fonseca HAR, Zimerman A, Monfardini F, Guimaraes HP, Pedrosa RP, Patriota R de LS, Patriota TLGC, Passos LCS, Dall'orto FTC, Nicolau JC. In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: a prespecified analysis of the VIP-ACS trial [Internet]. Vaccine. 2024 ; 42( 3): 496-504.[citado 2024 nov. 06 ] Available from: https://observatorio.fm.usp.br/handle/OPI/58827